![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG Medgenics Inc 15 April 2010 For release: 15 April 2010 SUSTAINED INTERFERON ALFA-2b (IFNa) PRODUCTION IN VITRO AND DELIVERY IN VIVO BY MEDGENICS DERMAL MICROORGAN BIOPUMPS SHOWCASED AT THE MAJOR EUROPEAN LIVER MEETING IN VIENNA Interferons have been shown to be effective treatment for chronic hepatitis C but their use has been associated with frequent side effects. Current treatment involves administration of peginterferon alpha injections weekly for 6 to 12 months. These injections generate high peak levels of interferon alpha (IFNa), which give rise to side effects, cause patient discomfort and lead some patients to discontinue treatment. The provision of consistent therapeutic levels of IFNa over a prolonged period of time could substantially reduce the side effect profile and improve the treatment of chronic hepatitis C, a disease that affects approximately 170 million people around the world. Medgenics, Inc. has a unique platform technology that creates dermis-based micro-organs, called Biopumps, capable of producing therapeutic proteins. A needle biopsy taken from a patient's own skin is used to prepare the Biopump. Medgenics has produced more than 5000 Biopumps, all of which have shown the capability for the sustained production of therapeutic proteins such as erythropoietin (EPO), IFNa, and others. In previous clinical studies, the Company has reported that a single administration of a few Biopumps producing the protein EPO has provided effective sustained treatment of anemia for more than a year. Patients with chronic kidney disease have been treated for periods of 6 to 16 months, without the need for additional EPO injections. On April 15th at the 2010 European Association for the Study of Liver Diseases (EASL) conference, Medgenics is presenting findings from key preclinical studies of Biopumps that produce IFNa intended for use in the treatment of chronic hepatitis C. In the two posters being presented, Medgenics reports (1) the reliable sustained production by Biopumps of potent human IFNain vitro, and (2) the in vivo production and delivery of human IFNa in SCID mice following the implantation of such Biopumps, called INFRADURE. In anticipated clinical use, as with the anemia clinical trial, each patient would receive the requisite number of INFRADURE Biopumps intended to provide their recommended daily IFNa dose. Dose levels can be increased by administering additional Biopumps, or reduced at any time by ablating one or more of Biopumps already administered. Key points arising from these posters are: To be commercially viable, IFNa Biopumps should each produce a target of > 1 µg/day of IFNa in vitro. The data presented in these posters showed that INFRADURE Biopumps provide sustained IFNa production at or exceeding 1-2 µg/day for at least 129 days in vitro. INFRADURE Biopumps produced from the skin of 7 patients, tested in vitro, all met the target potency criteria, despite moderate variability in the levels reached between patients' skin samples. Data are presented that show Biopumps manufactured from skin samples of the same patient producing different proteins: EPO and IFNa. This demonstrates the concept that the Biopump is a platform technology that has the potential for administration of a wide range of therapeutic proteins. Dose-dependent delivery and non-toxicity were demonstrated by in vivo studies in mice using INFRADURE Biopumps producing an IFNa dose appropriate for 70 kg humans. Two doses were administered: (1.3 µg/day and 4,0 µg/day, the "lower" and "higher" doses respectively were implanted into 20 g SCID mice. Dose response was seen on day 10 post-implantation: the "lower" group averaged 1700 pg/ml, and the "higher" group averaged 8,900 pg/ml. During the 3-4 months thereafter, the initially high levels of IFNa in mice were reduced to normal therapeutic levels in the10 pg/ml range. Serum levels of the "higher" dose animals were always greater than those of "lower" dose animals, and were well tolerated even though both doses greatly exceeded those that are used clinically. Necropsy revealed no abnormalities, indicating that even these large doses of IFNa from INFRADURE Biopumps were well tolerated. These findings parallel those found with EPODURE Biopumps tested under similar circumstances in vitro and in SCID mice. Based on the data reported at the EASL 2010 conference, Medgenics believes sustained IFNa treatment for chronic hepatitis C should be achievable by administering INFRADURE Biopumps to typical hepatitis C patients, in like manner to the results reported for EPODURE in treatment of anemia. Medgenics hopes to bring INFRADURE to clinical trials in the near future. Medgenics believes Biopumps will provide a potentially improved approach to therapy with fewer side effects and is likely to provide a more cost-effective treatment for hepatitis C and other chronic diseases. Biopumps represent an example of personalized medicine as the treatment is unique to the patient. Commenting on the data being presented, Professor Bruce R. Bacon, past president of the American Association for the Study of Liver Diseases said "The development of this novel Biopump technology provides the potential for an improved method for safe, effective interferon delivery that is cost-effective and efficacious." If you would like a copy of the posters and comparative data for EPODURE, please contact: Anna Dunphy (a.dunphy@defacto.com) or Mike Wort (m.wort@defacto.com). This information is provided by RNS The company news service from the London Stock Exchange END NRASFUSAIFSSELL
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions